Edoxaban
- Generic Name
- Edoxaban
- Brand Names
- Lixiana, Savaysa, Roteas
- Drug Type
- Small Molecule
- Chemical Formula
- C24H30ClN7O4S
- CAS Number
- 480449-70-5
- Unique Ingredient Identifier
- NDU3J18APO
- Background
Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic em...
- Indication
Edoxaban is indicated for reducing the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF). However, it should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg). It is also indicated for the tr...
- Associated Conditions
- Deep Vein Thrombosis, Pulmonary Embolism, Stroke, Systemic Embolism
- Associated Therapies
- -
Explore the Efficacy and Safety of edoxabaN in Patients After Heart Valve Repair or Bioprosthetic vaLve Replacement (ENAVLE Trial)
- Conditions
- Interventions
- First Posted Date
- 2017-08-09
- Last Posted Date
- 2020-01-02
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 220
- Registration Number
- NCT03244319
- Locations
- 🇰🇷
Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
Start or STop Anticoagulants Randomised Trial (SoSTART)
- Conditions
- Interventions
- First Posted Date
- 2017-05-15
- Last Posted Date
- 2022-04-08
- Lead Sponsor
- University of Edinburgh
- Target Recruit Count
- 203
- Registration Number
- NCT03153150
- Locations
- 🇬🇧
Frimley Park Hospital, Frimley, United Kingdom
🇬🇧Gloucestershire Royal Hospital, Gloucester, United Kingdom
🇬🇧Pinderfields Hospital, Wakefield, United Kingdom
A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- Scripps Health
- Target Recruit Count
- 75
- Registration Number
- NCT03088072
- Locations
- 🇺🇸
Scripps Health, La Jolla, California, United States
Comparison of Two Doses of Edoxaban Using Different Tests (Assays) and Clinical Outcomes
- First Posted Date
- 2016-11-16
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 607
- Registration Number
- NCT02964949
- Locations
- 🇱🇹
Vilnius University Hospital Santariskiu Clinic Public Institution, Vilnius, Lithuania
🇵🇱Synexus Polska Sp z o o Oddział we Wroclawiu, Wroclaw, Poland
🇷🇺FSHI "MSU of MoIA of RF of Kemerovo Region", Kemerovo, Russian Federation
Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Korea and Taiwan (ETNA-VTE-KOR-TWN)
- First Posted Date
- 2016-11-02
- Last Posted Date
- 2019-12-23
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 352
- Registration Number
- NCT02952599
- Locations
- 🇨🇳
Far Eastern Memorial Hospital, New Taipei City, Banciao District, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, Beitou District, Taiwan
🇨🇳Chang Gung Memorial Hospital, KaoHsiung, Kaohsiung, Niaosong District, Taiwan
Edoxaban Treatment in Routine Clinical Practice for Patients With Atrial Fibrillation in Korea and Taiwan (ETNA-AF-KOR-TWN)
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 3008
- Registration Number
- NCT02951039
- Locations
- 🇨🇳
Taipei Veterans General Hospital, Taipei, Beitou District, Taiwan
🇰🇷Soon Chun Hyang University Hospital Cheonan, Cheonan, Chungcheongnam-do, Korea, Republic of
🇰🇷GangNeung Asan Hospital, Gangneung, Gangwon-do, Korea, Republic of
Edoxaban Treatment in Routine Clinical Practice in Patients With Venous Thromboembolism in Europe
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2022-05-02
- Target Recruit Count
- 2809
- Registration Number
- NCT02943993
- Locations
- 🇩🇪
International Clinical Research GmbH, Germering, Germany
Edoxaban Treatment in Routine Clinical Practice for Patients With Non Valvular Atrial Fibrillation
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2022-06-01
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 13980
- Registration Number
- NCT02944019
- Locations
- 🇦🇹
Wilhelminenspital der Stadt Wien,Kardiologie,Wien, Wien, Austria
🇧🇪Clinique St-Jean, Cardiology, Bruxelles, Bruxelles, Belgium
🇦🇹Universitaetsklinik Graz, Onkologie, Graz, Graz, Austria
Edoxaban Treatment Versus Vitamin K Antagonist (VKA) in Patients With Atrial Fibrillation (AF) Undergoing Catheter Ablation
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2019-09-23
- Target Recruit Count
- 632
- Registration Number
- NCT02942576
- Locations
- 🇵🇱
Klinika Intensywnej Terapii Kardiologicznej, Łódź, Poland
🇧🇪Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇰🇷Seoul National University Hospital, Seoul, Jongno-gu, Korea, Republic of
ORal anticoaGulants in diAbetic and Nondiabetic Patients With nOn-valvular Atrial fibrillatioN (ORGANON)
- Conditions
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- University of Pavia
- Target Recruit Count
- 300
- Registration Number
- NCT02935855
- Locations
- 🇮🇹
IRCCS Policlinico San Matteo, Pavia, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.